A prospective clinical non-interventional analysis revealed that vitamin D3 deficiency predicts poor clinical outcomes in patients with metastatic melanoma under treatment with immune checkpoint Abs (PD1/CTLA4), BRAF or MEK1/2 inhibitors [96] and resulted in shortened overall and progression-free survival with higher tumor burden and IRAE. This evidence concerns the gene PDCD1 and metastatic melanoma.